DMRA
HEALTHCAREDamora Therapeutics Inc
AI Insight
What's Moving DMRA Today?
No stock-specific AI insight has been generated for DMRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.45$38.33
$22.94
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-2.68
Dividend Yield—
Dividend / Share—
ROE-89.5%
Profit Margin—
Debt / Equity—
Trading
Volume326K
Avg Volume (10D)—
Shares Outstanding61.6M
DMRA News
12 articles- Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeMotley Fool·May 30, 2026
- Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsYahoo Finance·May 12, 2026
- What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For ShareholdersYahoo Finance·May 8, 2026
- Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerYahoo Finance·May 5, 2026
- Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price MomentumYahoo Finance·May 5, 2026
- Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC SaysYahoo Finance·Apr 24, 2026
- What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?Yahoo Finance·Apr 20, 2026
- How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%Yahoo Finance·Apr 10, 2026
- Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?Yahoo Finance·Apr 1, 2026
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Mar 30, 2026
- Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of DirectorsYahoo Finance·Mar 23, 2026
- Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 19, 2026
All 12 articles loaded
Price Data
Open$23.21
Previous Close$23.89
Day High$24.53
Day Low$22.81
52 Week High$38.33
52 Week Low$2.45
52-Week Range
$2.45$38.33
$22.94
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-2.68
Dividend Yield—
Dividend / Share—
ROE-89.5%
Profit Margin—
Debt / Equity—
Trading
Volume326K
Avg Volume (10D)—
Shares Outstanding61.6M
About Damora Therapeutics Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—